Jolkinolide B alleviates renal fibrosis via anti-inflammation and inhibition of epithelial-mesenchymal transition in unilateral ureteral obstruction mice

Renal fibrosis is a critical pathological process lead to a progressive loss of renal function. Jolkinolide B (JB) is a natural compound with anti-inflammatory activity from Euphorbia fischeriana Steud. The study evaluated the effect of JB on renal fibrosis in mice with unilateral ureteral obstruction (UUO). The results showed that JB could decrease renal fibrotic area, reduce phosphorylation of NF-kappa B p65 and the release of TNF-alpha, IL-6 and IL-1 beta, restore the expression of vementin, alpha-SMA and E-cadherin, as well as TGF-beta 1 and p-smad2/3. In conclusion, JB might reduce renal fibrosis by inhibiting inflammation induced by NF-kappa B pathway and EMT mediated by TGF-beta 1/Smad pathway. [GRAPHICS] .

Automated summary

The study demonstrates that Jolkinolide B can reduce renal fibrosis by inhibiting inflammation through the NF-κB pathway and reversing epithelial-mesenchymal transition mediated by the TGF-β1/Smad pathway.